Scrub-a-Dub-Dub: FTC is Cleansing the Orange Book of Device Patents
FDA Law Blog: Biosimilars
JUNE 13, 2024
FTC, deep in its foray into the Orange Book, filed an Amicus Brief in the case arguing that the patents do not claim any FDA-approved drug. More specifically, the Court concluded that “the Inhaler Patents do not claim the drug for which the applicant submitted the application ” (emphasis added).
Let's personalize your content